High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent

Yu, Xin; Song, Sheng; Chen, Junjie; Scott, Michael J.; Fuhrhop, Ralph J.; Hall, Christopher S.; Gaffney, Patrick J.; Wickline, Samuel A.; Lanza, Gregory M.

doi:10.1002/1522-2594(200012)44:6<867::aid-mrm7>3.0.co;2-p

Cited by 230 publications

(139 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…However, there are significant problems in obtaining high-resolution diffusion images of carotid plaque in vivo, because of motion and low signal-to-noise ratio of these imaging techniques. Yu et al 22 noted that a novel fibrin-targeted paramagnetic nanoparticle contrast agent might allow sensitive early detection of unrecognized vascular pathology (thrombus) in high-risk patients. Recently, Yuan et al 9 showed that comparison of pre-and post-contrast-enhanced T1W images might further improve the accuracy of MRI for distinguishing plaque tissue types.…”

Section: Study Limitationsmentioning

confidence: 99%

Classification of Human Carotid Atherosclerotic Lesions With In Vivo Multicontrast Magnetic Resonance Imaging

et al. 2002

View full text Add to dashboard Cite

Background-Recent studies demonstrated that in vivo and ex vivo MRI can characterize the components of the carotid atherosclerotic plaque, such as fibrous tissue, lipid/necrotic core, calcium, hemorrhage, and thrombus. The purpose of this study was to determine whether in vivo high-resolution multicontrast MRI could accurately classify human carotid atherosclerotic plaque according to the American Heart Association classification. Methods and Results-Sixty consecutive patients (mean age 70 years; 54 males) scheduled for carotid endarterectomy were imaged with a 1.5-T scanner after informed consent was obtained. A standardized protocol was used to obtain 4 different contrast-weighted images (time of flight and T1-, PD-, and T2-weighted) of the carotid arteries. Best voxel size was 0.25ϫ0.25ϫ1 mm 3 . Carotid plaques were removed intact and processed for histological examination. Both MR images and histological sections were independently reviewed, categorized, and compared. Overall, the classification obtained by MRI and the American Heart Association classifications showed good agreement, with Cohen's (95% CI) of 0.74 (0.67 to 0.82) and weighted of 0.79. The sensitivity and specificity, respectively, of MRI classification were as follows: type I-II lesions, 67% and 100%; type III lesions, 81% and 98%; type IV-V lesions, 84% and 90%; type VI lesions, 82% and 91%; type VII lesions, 80% and 94%; and type VIII lesions, 56% and 100%. Conclusions-In vivo high-resolution multicontrast MRI is capable of classifying intermediate to advanced atherosclerotic lesions in the human carotid artery and is also capable of distinguishing advanced lesions from early and intermediate atherosclerotic plaque.

show abstract

Section: Study Limitationsmentioning

confidence: 99%

Classification of Human Carotid Atherosclerotic Lesions With In Vivo Multicontrast Magnetic Resonance Imaging

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Although originally developed for applications such as measuring ICAM-1 expression in autoimmune encephalitis [107], or for imaging fibrin-rich clots in an animal model of human thrombus formation [108], these novel molecular imaging approaches could be extended or adapted to image the same or similar targets in an "angiogenic" milieu. The use of targeted contrast agents in conjunction with the functional imaging techniques described earlier has begun to provide unique opportunities for understanding receptor-mediated pathways in tumor angiogenesis using MRI.…”

Section: Molecular Mr Imaging Of Tumor Angiogenesismentioning

confidence: 99%

Circulating and imaging markers for angiogenesis

Pathak

Hochfeld

et al. 2008

Angiogenesis

View full text Add to dashboard Cite

Abundant preclinical and indirect clinical data have for several decades convincingly supported the notion that anti-angiogenesis is an effective strategy for the inhibition of tumor growth. The recent success achieved in patients with metastatic colon carcinoma using a neutralizing antibody directed against vascular endothelial growth factor (VEGF) has translated preclinical optimism into a clinical reality.With this transformation in the field of angiogenesis has come a need for reliable surrogate markers. A surrogate marker by definition serves as a substitute for the underlying process in question, and in the case of angiogenesis, microvessel density (usually in so-called "hot-spots") has until now been the most widely used parameter. However, this parameter is more akin to a static "snapshot" and does not lend itself either to the dynamic in situ assessment of the status of the tumor microvasculature or to the molecular factors that regulate its growth and involution. This has led to an acute need for developing circulating and imaging markers of angiogenesis that can be monitored in vivo at repeated intervals in large number of patients with a variety of tumors in a non-invasive manner. Such markers of angiogenesis are the subject of this review.

show abstract

“…These can be detected with standard imaging equipment i.e. liquid perfluorocarbon nanoparticles [6,20,21]. .…”

Section: Possible Imaging Applicationsmentioning

confidence: 99%

“…MRI and ultrasound use paramagnetic polymerized liposomes bearing antibody ligands to neovascular integrins V 3 [7]. Similarly, liquid perfluorocarbon nanoparticle emulsions targeted to V 3 integrins permit fibrin visualization in thrombi [21] and carotid plaques ex vivo [22]. The maximum T1 per molecule binding site for a complex of paramagnetic perflurocarbon agents can give sensitivity in the picomolar range of concentrations [23].…”

Section: Possible Imaging Applicationsmentioning

confidence: 99%

New applications of nanoparticles in cardiovascular imaging

Sharma

Kwon

2007

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

Nanotechnology involves working at the atomic, molecular, and macromolecular levels including imaging. Recently, four areas have emerged in cardiovascular imaging: 1. Targeted therapeutics to deliver cardioprotective drugs at the target sites they are needed; 2. Myocardial tissue engineering to replace the defective valves, damaged heart muscle, clogged blood vessels and myocardium; 3. Molecular imaging using ''smart'' imaging agents in targeted therapeutics and imaging; 4. Biosensors and myocardial diagnostics. Several approaches to nanoparticles i.e. dendrimers, liposomes, polymer delivery molecules, cantilevers, nanoscaffolds, nanofibers are potential candidates in cardiac visualization. The extracellular matrix plays a significant role by chemokines, cytokines and growth factors. The limitations of these emerging techniques and a new possibility of MRI visualization of mouse cardiac atheroma by superparamagnetic iron-oxide gadolinium-apoferritin (SPIOA) and myoglobin (SPIOM), for targeted functional and molecular imaging of atherosclerosis are highlighted in this paper. These emerging techniques provide an opportunity for tracking functional and structural changes in myocardium and heart tissue.

show abstract

High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent

Cited by 230 publications

References 29 publications

Classification of Human Carotid Atherosclerotic Lesions With In Vivo Multicontrast Magnetic Resonance Imaging

Classification of Human Carotid Atherosclerotic Lesions With In Vivo Multicontrast Magnetic Resonance Imaging

Circulating and imaging markers for angiogenesis

New applications of nanoparticles in cardiovascular imaging

Contact Info

Product

Resources

About